Artiva Biotherapeutics | ApexOnco - Clinical Trials news and analysis

x

“The insights provided by the analysts are great”

Andrea Gnirke-Maier

Director New Product Planning

Morphosys

Click here for more information

Natural killer cells attacking cancer cell

Interviews Trial results

3 January 2024

Affimed looks to reverse a share price collapse

Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.

Subscribe to Artiva Biotherapeutics